The General Services Administration awarded a Federal Supply Schedule contract to Vifor (International) AG on May 1, 2026, under VA Schedule 65 IB (Drugs, Pharmaceuticals, & Hematology Related Products), with a ceiling value of $750,000 and an ultimate completion date of April 30, 2031. The award is administered for Veterans Integrated Service Network 12.
The contract covers specialized pharmaceutical products including MIRCERA (methoxy polyethylene glycol-epoetin beta) for anemia treatment, KORSUVA (difelikefalin) for pruritus, and KRYSTEXXA (pegloticase) for gout treatment, among other pharmaceutical solutions. Performance is nationwide across Department of Veterans Affairs medical facilities. Vifor is a Swiss-based pharmaceutical manufacturer registered with SAM.gov as an international organization and classified as a for-profit manufacturer of goods.
Recent ordering activity under the VA's pharmaceutical supply contracts shows delivery orders issued to Vifor ranging from approximately $65 to $11,310.02 across multiple Veterans Integrated Service Networks (VISN 5, VISN 12, VISN 20, and VISN 21) spanning December 2023 through January 2026. The company also holds a $150,000 Blanket Purchase Agreement under the same schedule for KORSUVA (awarded June 25, 2024, completion June 24, 2026) and a substantially larger $23.8 million BPA for MIRCERA, both structured as single-award vehicles to streamline procurement across the VA's veteran healthcare network. All orders are issued on a firm-fixed-price basis without set-aside designations.